Skip to navigation bar Skip to breadcrumbs Skip to page content
clear place holder Browse All Topics Envelope icon E-mail Updates Teal square Text size:  a A A
You are here: HomeRecommendations for Primary Care PracticePublished RecommendationsRecommendation SummaryFinal Recommendation Statement : Final Recommendation Statement

Final Recommendation Statement

Testicular Cancer: Screening, April 2011

Recommendations made by the USPSTF are independent of the U.S. government. They should not be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.

Recommendation Summary

Summary of Recommendation and Evidence

PopulationRecommendationGrade
(What's This?)
Adolescent and Adult Men

The USPSTF recommends against screening for testicular cancer in adolescent or adult men. 

The USPSTF recommends against the service. There is moderate or high certainty that the service has no net benefit or that the harms outweigh the benefits

Select for a Clinical Summary of this recommendation.

Preface

This Recommendation Statement was first published in Annals of Internal Medicine in April 2011 (Ann Intern Med 2011;154:483-486).

Rationale

Importance

Testicular cancer (a primary germ-cell tumor of the testis) is the most common cancer among males aged 15 to 34 years. However, with an annual incidence rate of 5.4 cases per 100,000 males, testicular cancer is relatively rare compared with other types of cancer.

Detection

Most cases of testicular cancer are discovered accidentally by patients or their partners. There is inadequate evidence that screening by clinician examination or patient self-examination has a higher yield or greater accuracy for detecting testicular cancer at earlier (and more curable) stages.

Benefits of Detection and Early Intervention

Based on the low incidence of this condition and favorable outcomes of treatment, even in cases of advanced disease, there is adequate evidence that the benefits of screening for testicular cancer are small to none.

Harms of Detection and Early Intervention

Potential harms associated with screening for testicular cancer include false-positive results, anxiety, and harms from diagnostic tests or procedures. The USPSTF found no new evidence on potential harms of screening and concluded that these harms are no greater than small.

USPSTF Assessment

The USPSTF concludes that there is moderate certainty that screening for testicular cancer has no net benefit.

Clinical Considerations

Patient Population Under Consideration

This recommendation applies to asymptomatic adolescent or adult males. The USPSTF did not review the evidence for screening males with a history of cryptorchidism.

Screening Tests

The sensitivity, specificity, and positive predictive value of testicular examination in asymptomatic patients are unknown. Screening examinations performed by patients or clinicians are unlikely to provide meaningful health benefits because of the low incidence and high survival rate of testicular cancer, even when it is detected at symptomatic stages1.

Treatment

Management of testicular cancer consists of orchiectomy and may include other surgery, radiation therapy, and chemotherapy, depending on the disease stage and tumor type. Regardless of disease stage, more than 90% of all newly diagnosed cases of testicular cancer will be cured2.

Useful Resources

The National Cancer Institute’s Physician Data Query, available at www.cancer.gov/cancertopics/pdq, is a comprehensive database that contains summaries on a wide range of cancer-related topics for health professionals and patients, including testicular cancer screening and treatment.

Discussion

In 2004, the USPSTF reviewed the evidence for screening for testicular cancer and recommended against screening adolescent or adult males3. In 2009, the USPSTF performed a brief literature review4 and found no new evidence that would warrant a change in its recommendation. Therefore, the USPSTF reaffirms its recommendation against screening adolescent or adult males for testicular cancer by clinician examination or patient self-examination. The previous recommendation statement and evidence report, as well as the summary of the updated literature search, are available at www.uspreventiveservicestaskforce.org/uspstf/uspstest.htm 5.

Response to Public Comments

A draft version of this recommendation statement was posted for public comment on the USPSTF Web site from 21 September through 19 October 2010. Some comments requested clarification about whether the USPSTF’s definition of screening includes patient self-examination in addition to clinician examination. Other comments expressed concern that this statement might discourage patients with testicular symptoms from seeking appropriate care. In response, the USPSTF revised the Clinical Considerations section to address these issues.

Recommendations of Others

The American Academy of Family Physicians recommends against routine screening for testicular cancer in asymptomatic adolescent and adult males6. The American Academy of Pediatrics does not include screening for testicular cancer in its recommendations for preventive health care7. Finally, the American Cancer Society does not recommend testicular self-examination8.

Members of the U.S. Preventive Services Task Force

Members of the U.S. Preventive Services Task Force at the time this recommendation was finalized† are Ned Calonge, MD, MPH, Chair (The Colorado Trust, Denver, Colorado); Kristin Bibbins-Domingo, MD, PhD (University of California, San Francisco, San Francisco, California); Adelita Gonzales Cantu, RN, PhD (University of Texas Health Science Center, San Antonio, Texas); Susan Curry, PhD (University of Iowa College of Public Health, Iowa City, Iowa); Allen J. Dietrich, MD (Dartmouth Medical School, Hanover, New Hampshire); Glenn Flores, MD (University of Texas Southwestern, Dallas, Texas); David Grossman, MD (Group Health Cooperative, Seattle, Washington); George Isham, MD, MS (HealthPartners, Minneapolis, Minnesota); Michael L. LeFevre, MD, MSPH (University of Missouri School of Medicine, Columbia, Missouri); Rosanne M. Leipzig, MD, PhD (Mount Sinai School of Medicine, New York, New York); Joy A. Melnikow, MD, MPH (University of California, Davis, Medical Center, Sacramento, California); Bernadette Melnyk, PhD, RN (Arizona State University College of Nursing & Healthcare Innovation, Phoenix, Arizona); Wanda Nicholson, MD, MPH (Johns Hopkins School of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland); Carolina Reyes, MD (University of Southern California, Los Angeles, California); J. Sanford Schwartz, MD (University of Pennsylvania Medical School and the Wharton School, Philadelphia, Pennsylvania); and Timothy Wilt, MD, MPH (University of Minnesota Department of Medicine and Minneapolis Veteran Affairs Medical Center, Minneapolis, Minnesota).

† For a list of current Task Force members, go to www.uspreventiveservicestaskforce.org/about.htm#Members.

Disclaimer: Recommendations made by the USPSTF are independent of the U.S. government. They should not be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.

Financial Support: The USPSTF is an independent, voluntary body. The U.S. Congress mandates that the Agency for Healthcare Research and Quality support the operations of the USPSTF.

Copyright and Source Information

This document is in the public domain within the United States.

Requests for Single Reprints: Reprints are available from the USPSTF Web site (www.uspreventiveservicestaskforce.org).

Source: U.S. Preventive Services Task Force. Screening for testicular cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med 2011;154:483-486.

References:
  1. U.S. Preventive Services Task Force. Screening for testicular cancer. In: Guide to Clinical Preventive Services, 2nd ed. Washington, DC: U.S. Department of Health and Human Services; 1996:153-7.
  2. National Cancer Institute. Testicular Cancer Treatment (PDQ) Summary: Health Professional Version. Bethesda, MD: National Cancer Institute; 2010. Accessed at www.cancer.gov/cancertopics/pdq/screening/testicular/HealthProfessional on 19 August 2010.
  3. U.S. Preventive Services Task Force. Screening for Testicular Cancer: Recommendation Statement. Rockville, MD: Agency for Healthcare Research and Quality; 2004.
  4. Lin K, Sharangpani R. Screening for testicular cancer: an evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2010;153:396-9. [PMID: 20855803]
  5. U.S. Preventive Services Task Force. Screening for Testicular Cancer: Brief Evidence Update. Rockville, MD: Agency for Healthcare Research and Quality; 2004.
  6. American Academy of Family Physicians. Summary of Recommendations for Clinical Preventive Services. Leawood, KS: American Academy of Family Physicians; 2010. Accessed at www.aafp.org/online/etc/medialib/aafp_org/documents/clinical/CPS/rcps08-2005.Par.0001.File.tmp/June2010.pdf on 19 August 2010. (PDF Help)
  7. American Academy of Pediatrics Committee on Practice and Ambulatory Medicine and Bright Futures Steering Committee. Recommendations for preventive pediatric health care. Pediatrics. 2007;120:1376.
  8. American Cancer Society. American Cancer Society Guidelines for the Early Detection of Cancer. Atlanta: American Cancer Society; 2010. Accessed at www.cancer.org/Healthy/FindCancerEarly/CancerScreeningGuidelines/american-cancer-society-guidelines-for-the-early-detection-of-cancer on 19 August 2010. (PDF Help)
Current as of: April 2011

Internet Citation: Final Recommendation Statement: Testicular Cancer: Screening. U.S. Preventive Services Task Force. October 2014.
http://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/testicular-cancer-screening

USPSTF Program Office   5600 Fishers Lane, Mail Stop 06E53A, Rockville, MD 20857